(Q37947915)

25 August 2017

Pathological work up of the primary tumor: getting the proper information out of it. (English)

1 reference

25 August 2017

1

Giuseppe Viale

1 reference

25 August 2017

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

20 Suppl 3

1 reference

25 August 2017

S82-6

1 reference

Triple-negative breast cancer: disease entity or title of convenience?

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Conservative surgery in patients with multifocal/multicentric breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

Is the Ki-67 labelling index ready for clinical use?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970300-9

7 January 2021

10.1016/S0960-9776(11)70300-9

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22015299